Table 1 Basic characteristics of included studies
Author, year | Country | No. | Stage | Follow-up | Preoperative chemoradiotherapy | Curative surgical resection | Postoperative adjuvant chemotherapy no. | PD-L1 (%) | HR | Cutoff for positive |
|---|---|---|---|---|---|---|---|---|---|---|
Enkhbat, 2018 [15] | Japan | 116 | II–III | 52 months (mean) | NA | YES | 57 | 52/116 | 3.873 | Score > 3 (intensity + area) |
Masugi, 2016 [35] | America | 450 | I–IV | > 5 years | NA | YSE | NA | 121/450 | 1.124 | Score = 1 (intensity) |
117/450 | 0.980 | Score = 2 (intensity) | ||||||||
139/450 | 1.042 | Score = 3 (intensity) | ||||||||
26/450 | 1.370 | Score = 4 (intensity) | ||||||||
Saigusa, 2016 [16] | Japan | 90 | I–IV | > 6 months | YES | YES | 90 | 36/90 | 2.452 | Score ≥ 2 (intensity) |
Zhu, 2015 [36] | China | 120 | NA | 39 months (mean) | NA | YES | NA | 28/120 | 0.692 | Score > 4 (intensity + area) |
Liang, 2014 [17] | China | 185 | I–IV | > 5 years | NA | YES | NA | 102/185 | 1.740 | Score > 4 (intensity + area) |
Droeser, 2014 [37] | Switzerland | 1420 | NA | > 5 years | NA | YES | NA | 495/1420 | 0.92 | Subjective evaluation |
Hamada, 2017 [20] | America | 384 | I–IV | > 5 years | NA | YES | NA | 211/384 | 1.20 | Score ≥ 2 (intensity + area) |
Lee, 2018 [18] | Korea | 336 | I–IV | 52 months (mean) | NA | YES | NOT | 15/336 | 3.785 | Area > 1% |
Li, 2016 [19] | China | 276 | NA | 61 months (mean) | NA | YES | 189 | 138/276 | 1.048 | Score > 4 (intensity + area) |
Miller, 2017 [38] | Australia | 104 | III | 82.5 months (mean) | NA | YES | 89 | 60/104 | 1.00 | Subjective evaluation |